Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Administration
6 evidence topics · 6 sources
Instructions for use, injection sites, and storage
No evidence found.
Subcutaneous formulation: once-weekly subcutaneous injection in the phase 3 trials
Subcutaneous formulation: dosing without regard to fasting in the phase 2 trial
Subcutaneous formulation: vial and syringe, then an autoinjector after a bioequivalence study
Subcutaneous formulation: autoinjector use and clinic visit frequency in the phase 3 trials
Subcutaneous formulation: vial and syringe in the maintenance study
Oral formulation: administration relative to food, water, and other oral medications
No evidence found.